EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preoperative plasma fibrinogen and C-reactive protein/albumin ratio as prognostic biomarkers for pancreatic carcinoma

Xiaopeng Chen, Zhaohui Chen, Jianyang Guo, Zhe Xiu, Huangxiang Chen

Frontiers in Oncology · 01.03.2024 · 14

DOI: 10.3389/fonc.2024.1301059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 01.03.2024. Verfasst von Xiaopeng Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The Second Hospital of Longyan, Longyan, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Pancreatic carcinoma is characterised by high aggressiveness and a bleak prognosis; optimising related treatment decisions depends on the availability of reliable prognostic markers. This study was designed to compare various blood biomarkers, such as neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR), C-reactive protein (CRP), albumin (Alb), plasma fibrinogen (PF), and CRP/Alb in patients with pancreatic carcinoma.

Methods

Our study retrospectively reviewed 250 patients with pancreatic carcinoma diagnosed between July 2007 and December 2018. The Cutoff Finder application was used to calculate the optimal values of CRP/Alb and PF. The Chi-square test or Fisher’s exact test was used to analyse the correlation of CRP/Alb and PF with other clinicopathological factors. Conducting univariate and multivariate analyses allowed further survival analysis of these prognostic factors.

Results

Multivariate analysis revealed that, in a cohort of 232 patients with pancreatic ductal adenocarcinoma (PDAC), the PF level exhibited statistical significance for overall survival (hazard ratio (HR) = 0.464; p = 0.023); however, this correlation was not found in the entire group of 250 patients with pancreatic carcinoma. Contrastingly, the CRP/Alb ratio was demonstrated statistical significance in both the entire pancreatic carcinoma cohort (HR = 0.471; p = 0.026) and the PDAC subgroup (HR = 0.484; p = 0.034). CRP/Alb and PF demonstrated a positive association (r=0.489, p<0.001) as indicated by Spearman’s rank correlation analysis. Additionally, in 232 PDAC patients, the combination of the CRP/Alb ratio and PF had synergistic effects on prognosis when compared with either the CRP/Alb ratio or the PF concentration alone.

Conclusion

PF concentration is a convenient, rapid, and noninvasive biomarker, and its combination with the CRP/Alb ratio could significantly enhance the accuracy of prognosis prediction in pancreatic carcinoma patients, especially those with the most common histological subtype of PDAC.

Schlagwörter

Stichwörter der Autor:innen

C-reactive protein/albuminoverall survivalpancreatic carcinomaplasma fibrinogenprognosis

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, The Second Hospital of Longyan, Longyan, China.
  • Department of the 9th Affiliated Hospital of Xi'an Jiaotong University, Xian, China.

Zitieren

APA

Chen, X., Chen, Z., Guo, J., Xiu, Z., & Chen, H. (2024). Preoperative plasma fibrinogen and C-reactive protein/albumin ratio as prognostic biomarkers for pancreatic carcinoma. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1301059

Vancouver

Chen X, Chen Z, Guo J, Xiu Z, Chen H. Preoperative plasma fibrinogen and C-reactive protein/albumin ratio as prognostic biomarkers for pancreatic carcinoma. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1301059

BibTeX
@article{Chen2024,
  author = {Chen, Xiaopeng and Chen, Zhaohui and Guo, Jianyang and Xiu, Zhe and Chen, Huangxiang},
  title = {Preoperative plasma fibrinogen and C-reactive protein/albumin ratio as prognostic biomarkers for pancreatic carcinoma},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1301059}
}
Kostenlos starten →